Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 695-700

  Pan, Jin Bing ^a   Hou, Yu Hong ^b   Zhang, Guo Jun ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Lung cancer; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CA 242 ANTIGEN; CARBOHYDRATE ANTIGEN 199, HUMAN; CARCINOEMBRYONIC ANTIGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; DRUG ANTAGONISM; FEMALE; GENETICS; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MUTATION;

ADENOCARCINOMA; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84877672788     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.695     Document Type: Article

References (39)

1. Addison CL, Ding K, Zhao H, et al. (2010). Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. J Clin Oncol, 28, 5247-56.
2. Bedi A, Pasricha PJ, Akhtar AJ,et al. (1995). Inhibition of apoptosis during development of colorectal cancer. Cancer Res, 55, 1811-6.
3. Bronte G, Rizzo S, La Paglia L, et al. (2010). Driver mutations and differential sensitivity to targeted therapies, a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev, 3, S21-9.
4. Cappuzzo F, Magrini E, Ceresoli GL,et al. (2004). Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst, 96, 1133-41.
5. Chen F, Luo X, Zhang J,et al. (2010). Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Med Oncol, 27, 950-7.
6. Costa DB, Kobayashi S, Tenen DG,et al. (2007). Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 58, 95-103.
7. Dong QG, Huang JS, Huang C,et al. (2005). The progress at target therapy in lung cancer and EGFR gene mutation profile in China. (in Chinese). Tumors, 25, 625-8.
8. Dong QG, Huang JS, Yang LM,et al. (2006). Epidermal growth factor receptor gene mutations in Chinese patients with adenocarcinoma of the lung. (in Chinese). Tumor 26, 271-5.
9. Duxbury MS, Ito H, Zinner MJ,et al. (2004). CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene, 23, 465-73.
10. Han C, Zou H, Ma J,et al. (2010). Comparison of EGFR and KRAS statusbetween primary non-small cell lung cancer and corresponding metastases, a systematic review and meta-analysis. (in Chinese). Zhongguo Fei Ai Za Zhi, 13, 882-91.
11. Han R, Zhong W, Zhao J,et al. (2011). Comparison of EGFR mutation status in paired pre-and post-chemotherapy serum for advanced pulmonary adenocarcinoma (in Chinese). Zhongguo Fei Ai Za Zhi, 14, 127-31.
12. Jemal A, Bray F, Center MM,et al. (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Jemal A, Siegel R, Xu J,et al. (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
14. Green MR (2004). Targeting targeted therapy. N Engl J Med, 350, 2191-3.
15. Jiang H (2009). Overview of gefitinib in non-smallcell lung cancer, an Asian perspective. Jpn J Clin Oncol, 39, 137-50.
16. Kim ES, Hirsh V, Mok T,et al. (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised phase III trial. Lancet, 372, 1809-18.
17. Kim TJ, Choi JJ, Kim WY,et al. (2008). Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci, 99, 31-8.
18. Kosaka T, Yatabe Y, Endoh H,et al. (2004). Mutations of the epidermal growth factor receptor gene in lung cancer, biological and clinical implications. Cancer Res, 64, 8919-23.
19. Lamerz R (1999). Role of tumour markers, cytogenetics. Ann Oncol, 4, 145-9.
20. Massarelli E, Andre F, Liu DD,et al. (2003). A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer, 39, 55-61.
21. Miller VA, Kris MG, Shah N,et al. (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9.
22. Mok TS, Wu YL, Thongprasert S,et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.
23. Mountain CF (1997). Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-7.
24. Mu XL, LI LY, HE QY (2006). The diversity of epidermal growth factor receptor tyrosine kinase domain mutations and clinical features. (in Chinese). Tumor, 26, 956-9.
25. Okamoto T, Nakamura T, Ikeda J,et al. (2005). Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer, 41, 1286-90.
26. Ou G, Hedberg M, Hörstedt P,et al. (2009). Proximal small intestinal microbiota and identification of rod-shaped bacteria associated with childhood celiac disease. Am J Gastroenterol, 104, 3058-67.
27. Paez JG, Jänne PA, Lee JC,et al. (2004). EGFR mutations in lung cancer, correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
28. Parkin DM, Bray F, Ferlay J,et al. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55,74-108.
29. Park K, Goto K (2006). A review of the benefit-risk profile ofgefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin, 22, 561-73.
30. Pfister DG, Johnson DH, Azzoli CG,et al. (2004). American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline, update 2003. J Clin Oncol, 22, 330-53.
31. Schiller JH, Harrington D, Belani CP,et al. (2002). Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
32. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. (2005). National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.
33. Shoji F, Yoshino I, Yano T,et al. (2007). Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer, 110, 2793-8.
34. Sordella R, Bell DW, Haber DA,et al. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 305, 1163-7.
35. Tsuchiya A, Koizumi M, Ohtani H (2009). World Health Organization Classification (2004)-based re-evaluation of 95 nonfunctioning "malignant" pancreatic endocrine tumors reported in Japan. Surg Today, 39, 500-9.
36. Tufman A, Huber RM (2010). Biological markers in lung cancer, A clinician's perspective. Cancer Biomark, 6, 123-35.
37. Yang SH, Mechanic LE, Yang P,et al. (2005). Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 11, 2106-10.
38. Yang X, Wang D, Li Z,et al. (2007). Clinicalsignificance of multiple tumor marker protein chip in monitoring the recurrence, progression and metastasis of lung cancer. (in Chinese). Zhongguo Fei Ai Za Zhi, 10, 296-300.
39. Yin GH, Liu Wei, Wu Yong (2009). Epidermal growth factor receptor gene mutations in Chinese patients with primary lung adenocarcinoma. (in Chinese). Chin J Gerontol, 29, 443-5.